A research team funded by the National Eye Institute have developed a new virus-like particle (VLP) to enhance how specialists edit proteins causing inherited diseases.
This new VLP system, called engineered nucleocytosolic vehicles for loading of programmable editors — or ENVLPE — efficiently corrected two mutations associated with blindness. The researchers anticipate this CRISPR gene editing approach also being used to treat other inherited diseases, such as cystic fibrosis and familial hypercholesterolemia.














